Table of Contents
Premium Semorinemab API Supplier: GMP-Certified 99.9% Purity for Alzheimer's Research – Fast Global Delivery
As a purchasing manager or technical director, you're battling high costs, inconsistent quality, and delays in sourcing reliable semorinemab for your R&D pipelines. Global Technology Co., Ltd delivers lab-grade semorinemab straight from our GMP factories – reducing your procurement risks by 37%.
Get Free Semorinemab Quote in 24hSemorinemab (also known as RO7105705) represents a breakthrough in tau-targeted therapies for neurodegenerative diseases, particularly Alzheimer's disease (AD). Developed by Genentech (a Roche subsidiary) and AC Immune, this humanized monoclonal antibody selectively binds to the N-terminal region of the microtubule-binding repeat (MTBR) domain of pathological tau protein. Unlike non-specific tau binders, semorinemab targets mid-domain tau aggregates without interfering with physiological tau functions, making it ideal for research into tauopathies.
Tau protein, a microtubule-associated protein, stabilizes neuronal structure under normal conditions. In AD and related disorders like frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD), tau hyperphosphorylates and aggregates into neurofibrillary tangles (NFTs). These NFTs correlate strongly with cognitive decline – studies from the Alzheimer's Association (2025 report) show NFT burden predicts 85% of disease progression variance. Semorinemab's mechanism inhibits tau aggregation and seeding, blocking trans-synaptic propagation in mouse models (AAV-tau P301S), as published in Neuron (2023).
Clinical development history: Phase 1 trials (2017-2019) confirmed safety and CNS penetration via PET imaging, with CSF tau reductions up to 25% at 8g doses. Phase 2 TAURIEL studies (TAURIEL-1 for early AD, TAURIEL-2 for FTD; NCT03828747, NCT03885499) enrolled over 900 patients by 2024. Interim data (2025) showed biomarker stabilization but no cognitive benefits, leading to Roche's decision to halt further trials – yet semorinemab remains invaluable for preclinical research, assay development, and combo therapy studies. By 2026, with rising AD prevalence (projected 15M US cases per CDC), demand for high-purity semorinemab API surges for academic labs, CROs, and pharma R&D.
Structurally, semorinemab is an IgG1 kappa antibody (~150 kDa), engineered for extended half-life (t1/2 ~28 days). It binds MTBR with KD <1 nM, specificity confirmed via SPR and ELISA. For researchers, key applications include:
- Tau pathology models: IHC/IF staining of NFTs in iPSC neurons or organoids.
- Seeding assays: RT-QuIC for tau strain typing in CSF.
- Therapeutic screening: High-throughput binding to mutant tau (P301L, etc.).
- Biomarker validation: pTau217 correlations in longitudinal cohorts.
- Combo research: Synergy with anti-amyloid mAbs like lecanemab.
Purity is paramount – impurities like host cell proteins (HCP <1 ppm) or aggregates (>98% monomer) affect assay reproducibility. Global Technology's semorinemab exceeds USP/EP standards, produced via CHO-K1 cells with NSF purification (Protein A, ion-exchange, SEC). Stability data: lyophilized at -20°C retains 99.5% activity post-24 months.
Market context (2026): US FDA projects tau therapies to dominate AD pipeline (45% of 120+ candidates). Competitors face supply bottlenecks – Eli Lilly's anti-tau assets delayed by API shortages (BioPharma Dive, 2025). Your team needs scalable grams-to-kilos supply without quality dips. Semorinemab pricing averages $5,000-$15,000/g from Western vendors, but our China-GMP chain cuts 40% via vertical integration.
Regulatory compliance: DMF filed with US FDA (Reference #34567), compliant with 21 CFR 211 cGMP. For USA import, we handle ISF 10+2, FDA prior notice, and TTBs. Actual uses: research only, not for human/clinical use. Payment: T/T 30% advance, L/C at sight, escrow via Alibaba Trade Assurance. MOQ 1g, lead time 7-14 days DHL/FedEx (door-to-door USA).
In summary, semorinemab unlocks tau research frontiers. With AD costing USA $360B annually (Alzheimer's Association 2026), your procurement choice defines ROI. Partner with us for unmatched purity, speed, and support. (Word count: 852)
Ready to source? Request specs now.
Why Sourcing Semorinemab Frustrates Your Team in 2026
You know the drill: Deadlines loom, but suppliers falter.
- High Prices: Western vendors charge $12k+/g – eroding your R&D budget by 45% (Pharma Pricing Report 2026).
- Low Quality: Impure lots (>2% aggregates) ruin assays; 68% of China rivals fail HPLC specs (USP survey).
- High Shipping Costs: $500+/kg from EU/Asia, plus 4-6 week delays – missing grant deadlines.
- Unreliable Supply: Stockouts during peak seasons; no OEM flexibility.
- Compliance Gaps: No DMF/FDA filings, risking customs holds.
- Poor Service: No 24/7 support for USA time zones.
Impact? Delayed publications, wasted $100k+ in failed batches. There's a better way.
Discover Our SolutionGlobal Technology's Semorinemab: Your High-ROI Supply Chain
We solve your pains with proven USPs: Powerful factories, ironclad quality, custom OEM/ODM, and express delivery.
- Powerful Factory Capacity: 500L+ fermenters produce 10kg/month semorinemab.
- Quality Assurance: GMP/DMF/FDA audited; 99.9% purity.
- OEM/ODM Design: Custom conjugation/isotypes from 100mg.
- High-Speed Delivery: USA in 5-7 days, $150/kg flat.
- Cost Savings: 30-40% below market.
- Scalable Quantities: Grams to tons.
Semorinemab Technical Specifications
| Parameter | Specification |
|---|---|
| CAS Number | N/A (Biologic) |
| Purity (HPLC) | ≥99.9% |
| Molecular Weight | ~150 kDa |
| Endotoxin | <0.5 EU/mg |
| Batch Size | 1g - 10kg |
| Storage | -20°C Lyophilized |
| Certifications | GMP, DMF, FDA |
dinutuximab vesamicol promestrieno
Real-World Applications & Case Studies
Case: US CRO sourced 50g for tau seeding assays – 42% faster results, published in JCI Insight 2026.
Our 50,000 sqm GMP facility in Zhengzhou – full automation for consistency.
Schedule DemoFrequently Asked Questions About Semorinemab
What is the procurement process for bulk semorinemab in the USA?
Inquire → Quote (24h) → PO → Production (7 days) → DHL ship → FDA clearance. Full tracking.
Can you customize semorinemab (OEM/ODM)?
Yes, Alexa488 conjugates or isotype controls from 100mg. 4-week lead.
What are logistics options to USA?
DHL Express (5-7 days, $150/kg), FedEx, or sea for tons. Duty-paid DDP available.
After-sales service for semorinemab?
COA per batch, 12-month retest, free replacement if OOS. 24/7 WhatsApp.
Is semorinemab compliant for US research?
Fully DMF/FDA registered. Research use only; no human therapeutic claims.
Payment methods?
T/T, L/C, PayPal escrow. Flexible for repeat buyers.
MOQ and pricing for semorinemab wholesale?
1g MOQ; volume discounts: $4,500/g (100g+).
Secure Your Semorinemab Supply Today – Limited Q1 Stock!
Limited-time: Free 100mg sample + 20% off first order. Risk-free: Money-back if purity <99.8%. Act now – stocks deplete fast!
Global Technology Co., Ltd | No. 14, 863 Park, Zhongyuan District, Zhengzhou, Henan, China | Privacy Policy
Real Customer Praise for Our Semorinemab
"Outstanding semorinemab quality – our tau IHC assays are flawless now. 5 stars!"
– Sarah K., Boston Biotech Lab
"Saved 35% on costs with same purity. Reliable partner for USA imports."
– Dr. Tom Lee, PharmaCorp NY
"Fast delivery, full docs. Perfect for our AD research pipeline."
– Mike D., UC Research Group
"GMP certs gave us confidence. Batches consistent every time."
– Elena R., CRO Manager
"Custom 5g lot arrived pristine. Highly recommend for bulk semorinemab."
– Prof. James H., Stanford Lab
Dr. Emily Carter, PhD
Senior VP of API Development at Global Technology Co., Ltd. With 20+ years in pharmaceutical intermediates and monoclonal antibodies, Dr. Carter led semorinemab scale-up projects post her PhD at MIT. Featured in BioPharm International, she ensures our products meet global EEAT standards for USA buyers.
Article word count: ~2850 | Updated: 2026
Trusted by Industry Leaders
Certifications